FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59. https://doi.org/10.1038/s41572-021-00293-y.

Article  PubMed  Google Scholar 

Ruscitti P, Esposito M, Gianneramo C, et al. Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study. Radiol Med. 2022;127(12):1400–6. https://doi.org/10.1007/s11547-022-01568-4.

Article  PubMed  PubMed Central  Google Scholar 

Poddubnyy D, Jadon DR, Van den Bosch F, Mease PJ, Gladman DD. Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheum. 2021;51(4):880–7. https://doi.org/10.1016/j.semarthrit.2021.06.006.

Article  PubMed  Google Scholar 

Pittam B, Gupta S, Harrison NL, Robertson S, Hughes DM, Zhao SS. Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(9):2199–206. https://doi.org/10.1093/rheumatology/keaa062.

Article  PubMed  Google Scholar 

Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology (Oxford). 2015;54(5):792–7. https://doi.org/10.1093/rheumatology/keu398.

Article  PubMed  Google Scholar 

Lubrano E, Scriffignano S, Perrotta FM. Multimorbidity and comorbidity in psoriatic arthritis - a perspective. Expert Rev Clin Immunol. 2020;16(10):963–72. https://doi.org/10.1080/1744666X.2021.1825941.

Article  CAS  PubMed  Google Scholar 

Caso F, Chimenti MS, Navarini L, et al. Metabolic syndrome and psoriatic arthritis: considerations for the clinician. Expert Rev Clin Immunol. 2020;16(4):409–20. https://doi.org/10.1080/1744666X.2020.1740593.

Article  CAS  PubMed  Google Scholar 

Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18(6):311–25. https://doi.org/10.1038/s41584-022-00776-6.

Article  CAS  PubMed  Google Scholar 

Ruscitti P, Esposito M, Di Cola I, et al. Cytokine profile characterization of naïve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum. Front Immunol. 2023;13(14):1229516. https://doi.org/10.3389/fimmu.2023.1229516.

Article  CAS  Google Scholar 

Vecellio M, Hake VX, Davidson C, Carena MC, Wordsworth BP, Selmi C. The IL-17/IL-23 axis and its genetic contribution to psoriatic arthritis. Front Immunol. 2021;7(11):596086. https://doi.org/10.3389/fimmu.2020.596086.

Article  CAS  Google Scholar 

Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskeletal Care. 2022;20 Suppl 1(Suppl 1):S12–21. https://doi.org/10.1002/msc.1694.

Article  PubMed  Google Scholar 

Ritchlin C. Navigating the diverse immune landscapes of psoriatic arthritis. Semin Immunopathol. 2021;43(2):279–90. https://doi.org/10.1007/s00281-021-00848-x.

Article  CAS  PubMed  Google Scholar 

Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–12. https://doi.org/10.1136/annrheumdis-2020-217159.

Article  PubMed  Google Scholar 

Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79. https://doi.org/10.1038/s41584-022-00798-0. (Erratum in: Nat Rev Rheumatol. 2022 Oct 10).

Article  PubMed  PubMed Central  Google Scholar 

Huang X, Shentu H, He Y, et al. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023. https://doi.org/10.1007/s12026-023-09366-4.

Article  PubMed  PubMed Central  Google Scholar 

Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–25. https://doi.org/10.1016/S0140-6736(20)30265-8. (Erratum in: Lancet. 2020 Apr 4;395(10230):1114).

Article  CAS  PubMed  Google Scholar 

Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2) a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–36. https://doi.org/10.1016/S0140-6736(20)30263-4. (Erratum in: Lancet. 2020 Apr 4;395(10230):1114).

Article  CAS  PubMed  Google Scholar 

Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359–69. https://doi.org/10.1136/annrheumdis-2021-220991.

Article  CAS  PubMed  Google Scholar 

Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–74. https://doi.org/10.1007/s12325-018-0805-y.

Article  PubMed  PubMed Central  Google Scholar 

Barnish MS, Turner S. The value of pragmatic and observational studies in health care and public health. Pragmat Obs Res. 2017;12(8):49–55. https://doi.org/10.2147/POR.S137701.

Article  Google Scholar 

Batrouni M, Comet D, Meunier JP. Real world studies, challenges, needs and trends from the industry. Value Health. 2014;17(7):A587–8. https://doi.org/10.1016/j.jval.2014.08.2006.

Article  CAS  PubMed  Google Scholar 

Pantano I, Mauro D, Romano F, et al. Real-life efficacy of guselkumab in patients with early psoriatic arthritis. Rheumatology (Oxford). 2022;61(3):1217–21. https://doi.org/10.1093/rheumatology/keab509.

Article  PubMed  Google Scholar 

Rocamora V, Crespi L, Ferran M, et al. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatol Ther. 2022;35(11):e15865. https://doi.org/10.1111/dth.15865.

Article  CAS  PubMed  Google Scholar 

Vaiopoulos AG, Dalamaga M, Katsimbri P, Koumourtzis M, Lampadaki K, Theodoropoulos K, Theotokoglou S, Kanelleas A, Syrmali A, Filippopoulou A, Zoupidou K, Katoulis A, Papadavid E. Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol. 2023;62(11):1404–1413. https://doi.org/10.1111/ijd.16849.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Ogdie A, Chakravarty SD, et al. Clinical characteristics of registry participants with psoriatic arthritis initiating guselkumab: an analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Drugs Real World Outcomes. 2022;9(4):617–28. https://doi.org/10.1007/s40801-022-00326-2.

Article  PubMed  PubMed Central  Google Scholar 

Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73. https://doi.org/10.1002/art.21972.

Article  PubMed  Google Scholar 

Rahman P, Boehncke WH, Mease PJ, et al. Safety of guselkumab with and without prior tumor necrosis factor inhibitor treatment: pooled results across 4 studies in patients with psoriatic arthritis. J Rheumatol. 2023;50(6):769–80. https://doi.org/10.3899/jrheum.220928.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Ogdie A, Tesser J, et al. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2023;10(6):1479–501. https://doi.org/10.1007/s40744-023-00582-w.

Article  PubMed  PubMed Central  Google Scholar 

Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3:e715–23.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Gladman DD, Poddubnyy D, et al. Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled discover-2 study. Rheumatol Ther. 2023;10(6):1637–53. https://doi.org/10.1007/s40744-023-00592-8.

Article  PubMed  PubMed Central  Google Scholar 

Ritchlin CT, Deodhar A, Boehncke WH, et al. Multidomain Efficacy and safety of guselkumab through 1 year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase 3, randomized, placebo-controlled discover-1 study. ACR Open Rheumatol. 2023;5(3):149–64. https://doi.org/10.1002/acr2.11523.

Article  PubMed  PubMed Central  Google Scholar 

Braun J, Landewé RB. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related “physician-reported spondylitis”? Ann Rheum Dis. 2022;81(4):466–8. https://doi.org/10.1136/annrheumdis-2021-221422.

Article  CAS  PubMed  Google Scholar 

Siebert S, Behrens F, Lubrano E, et al. PsABIOnd study and eDaily substudy design: long-term effectiveness and safety of guselkumab and IL-17 inhibitors in routine clinical practice in patients with psoriatic arthritis. Rheumatol Ther. 2023;10(2):489–505. https://doi.org/10.1007/s40744-022-00518-w.

Article  PubMed